Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
Rhea-AI Summary
Propanc Biopharma (Nasdaq:PPCB) reported Q3 2025/26 results and key corporate milestones. The company is advancing lead asset PRP toward a Phase 1b first-in-human study in advanced solid tumor patients and strengthening its anti-aging and cancer research portfolio via a multi-year Spanish university collaboration.
Propanc entered a private placement for up to $100 million, received $2 million by March 31 plus a subsequent $0.5 million tranche, reduced liabilities by $2.10 million and cut convertible notes to $55,000, ending the quarter with $14.33 million in assets and $443,702 in cash.
AI-generated analysis. Not financial advice.
Positive
- Private placement facility for up to $100 million to accelerate clinical development
- Total liabilities reduced by $2.10 million in the quarter
- Convertible notes cut to $55,000 from $538,000
- Net cash from financing activities of $4.47 million
- Quarter-end total assets of $14.33 million
- Service and research agreements support PRP clinical readiness and new anti-aging IP
Negative
- Quarter-end cash balance limited to $443,702 despite new financing
- Ongoing operations and R&D depend on continued access to the financing facility
News Market Reaction – PPCB
On the day this news was published, PPCB declined 6.98%, reflecting a notable negative market reaction. Argus tracked a trough of -19.0% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $120K from the company's valuation, bringing the market cap to $1.60M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PPCB fell 21.4% while close peers showed mixed, mostly modest moves (e.g., AKTX +8.82%, LIXT +1.61%, ALLR -3.23%, RNTX -2.59%, BOLD 0%). Momentum scanner data also flags mixed peer directions, pointing to a stock-specific reaction rather than a coordinated biotech sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 13 | Reverse stock split | Neutral | -21.4% | 1-for-25 reverse split to help regain Nasdaq $1 bid compliance. |
| Mar 24 | Research collaboration | Positive | -5.9% | Multi-year anti-aging and cancer research deal with Spanish universities. |
| Mar 12 | Preclinical efficacy data | Positive | -13.6% | Preclinical PRP data showing >85% tumor inhibition and plan for FIH trials. |
| Mar 10 | PK assay agreement | Positive | -20.5% | Service agreement with FyoniBio to develop an LC-MS PK assay for PRP. |
| Mar 03 | Program overview | Positive | -5.2% | Update on PRP preclinical profile, orphan status, funding facility and FIH plans. |
Recent history shows PPCB often trading lower after ostensibly positive corporate, financing, and R&D announcements, suggesting a pattern of negative price reactions to news.
Over the last six months, Propanc Biopharma issued several updates around PRP and financing. In March 2026, it highlighted >85% tumor growth inhibition data and plans for a Phase 1b FIH trial, plus an LC‑MS PK assay agreement and a multi‑year Spanish research collaboration, yet shares fell after each release. A May 18, 2026 reverse stock split to support Nasdaq compliance also saw a sharp decline. Today’s quarterly and corporate update, including use of a large financing facility, arrives against this backdrop of repeated selloffs following news.
Market Pulse Summary
The stock moved -7.0% in the session following this news. The decline reflects ongoing skepticism despite updates on PRP’s advancement and added financing, including a facility up to $100 million and Q3 cash of $443,702. Historically, PPCB has often traded lower after positive-sounding news, with several March 2026 announcements followed by declines of 5–20%. Persistent losses, equity-linked financing, and a very low share price relative to the 200-day MA 1.36 could leave the stock vulnerable to continued pressure.
Key Terms
pharmacokinetics medical
liquid chromatography-mass spectrometry (LC-MS) technical
first-in-human (FIH) medical
senescence medical
proenzymes medical
GMP technical
CROs technical
CDMOs technical
AI-generated analysis. Not financial advice.
Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases
MELBOURNE, Australia, May 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30).
Corporate and R&D Highlights
Executes Service Agreement with FyoniBio GmbH to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
Management has executed a service agreement with FyoniBio GmbH (formerly Glycotope, est. 2010), a German Contract Development Organization (CDO) based in Berlin for establishing and validating a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay. The objective is to quantify the Company’s lead asset, PRP, consisting of two proenzymes trypsinogen and chymotrypsinogen, as well as their activated enzyme forms trypsin and chymotrypsin from human serum during the Phase 1b, First-In-Human (FIH) study in advanced cancer patients suffering from solid tumors.
Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
A multi-year Joint Research Collaboration Agreement has been established with the Universities of Jaén (UJA) and Granada (UGR), Spain. The collaboration involves the evaluation of a senescence-modulating (i.e., anti-aging) compound to mitigate senescence and to complete experiments to further support the claims of recently filed fibrosis and cancer related patent applications, requested by Propanc Biopharma Inc. to the research group “Biological Technologies of The University of Jaén” and UGR’s Research Group, “Advanced Therapies: Differentiation, Regeneration and Cancer.”
Corporate and Financial Updates
Propanc entered into a private placement agreement for up to
Q3 Financial Summary (Quarter Ended March 31, 2026)
- Total assets:
$14.33 million - Total liabilities reduced by
$2.10 million - Convertible notes reduced to
$55,000 (from$538,000) - Net cash from financing activities:
$4.47 million - Quarter-end cash:
$443,702 $0.5 million tranche from the Series C facility subsequently received
The Company expects the financing facility to continually support planned R&D activities, including advancement of PRP and Rec-PRP.
Management Commentary
“We are entering a pivotal phase of development for the Company’s lead asset, PRP, which is progressing to a world first, Phase 1b, First-In-Human study, in 30 – 40 advanced cancer patients suffering from solid tumors. Execution of an agreement with Fyoni Bio will facilitate method development and validation of the pharmacokinetics method in preparation for the pivotal clinical study. In addition, management is engaging with CDMOs (Contract Development and Manufacturing Organizations) for the GMP manufacture of PRP for supply of the finished drug product, CROs (Clinical Research Organizations) to discuss management of future clinical trial operations, as well as preparing regulatory documentation for the Clinical Trial Application targeting submission later this year,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “Additionally, our multi-year research agreement with the Universities of Jaén and Granada will continue to support, strengthen and grow our intellectual property around the use of proenzymes not just in cancer, but also focusing on cell rejuvenation to overcome age-related, chronic diseases, such as fibrosis. I am confident we are on the right path to execute a rapid transformation of our Company to clinical stage for a range of incurable diseases which can offer renewed hope for patients.”
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
| PROPANC BIOPHARMA, INC. AND SUBSIDIARY | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| March 31, 2026 | June 30, 2025 | ||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| CURRENT ASSETS: | |||||||
| Cash | $ | 443,702 | $ | 12,088 | |||
| GST tax receivable | 11,057 | 5,302 | |||||
| Prepaid expenses - current portion | 7,733,625 | 8,334,046 | |||||
| Other current assets | 35,104 | 1,380 | |||||
| TOTAL CURRENT ASSETS | 8,223,488 | 8,352,816 | |||||
| Deferred offering costs | - | 291,773 | |||||
| Prepaid expenses - long-term portion | 6,057,422 | 10,925,835 | |||||
| Security deposit - related party | 2,065 | 1,971 | |||||
| Operating lease right-of-use assets, net - related party | 46,584 | 59,413 | |||||
| Property and equipment, net | 4,221 | - | |||||
| TOTAL ASSETS | $ | 14,333,780 | $ | 19,631,808 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| CURRENT LIABILITIES: | |||||||
| Accounts payable | $ | 973,692 | $ | 1,249,596 | |||
| Accrued expenses and other payables | 942,376 | 1,486,550 | |||||
| Accrued interest | 123,181 | 190,795 | |||||
| Loans payable | - | 65,280 | |||||
| Loans payable - related parties, net of discount | 465,282 | 415,329 | |||||
| Notes payable, net of discount | - | 543,312 | |||||
| Convertible notes, net of discounts and including put premiums | 55,000 | 537,921 | |||||
| Operating lease liability - related party, current portion | 23,324 | 17,664 | |||||
| Warrant liability | 104,313 | - | |||||
| Embedded conversion option liabilities | 50,273 | 403,892 | |||||
| Employee benefit liability | 738,187 | 667,901 | |||||
| TOTAL CURRENT LIABILITIES | 3,475,628 | 5,578,240 | |||||
| NON-CURRENT LIABILITIES: | |||||||
| Loan payable - long-term - related party, net of discount | - | 105,627 | |||||
| Operating lease liability - long-term portion - related party | 30,267 | 41,749 | |||||
| TOTAL NON-CURRENT LIABILITIES | 30,267 | 147,376 | |||||
| TOTAL LIABILITIES | $ | 3,505,895 | $ | 5,725,616 | |||
| Temporary Equity – Convertible Preferred Stock Series C - | $ | 1,000,000 | $ | - | |||
| Commitments and Contingencies (See Note 9) | |||||||
| STOCKHOLDERS’ EQUITY: | |||||||
| Preferred stock, 1,500,005 shares authorized, | |||||||
| Series A preferred stock, | $ | - | $ | - | |||
| Series B preferred stock, | - | - | |||||
| Common stock, | 21,860 | 11,612 | |||||
| Common stock issuable (33,007,750 and 7,750 shares as of March 31, 2026 and June 30, 2025, respectively) | 33,008 | 8 | |||||
| Additional paid-in capital | 149,427,962 | 138,243,652 | |||||
| Accumulated other comprehensive income | 1,234,766 | 1,318,917 | |||||
| Accumulated deficit | (140,843,234 | ) | (125,621,520 | ) | |||
| Treasury stock ( | (46,477 | ) | (46,477 | ) | |||
| TOTAL STOCKHOLDERS’ EQUITY | 9,827,885 | 13,906,192 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 14,333,780 | $ | 19,631,808 | |||
| PROPANC BIOPHARMA, INC. AND SUBSIDIARY | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) | |||||||||||||||
| (Unaudited) | |||||||||||||||
| For the three months ended March 31, | For the nine months ended March 31, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| REVENUE | |||||||||||||||
| Revenue | $ | - | $ | - | $ | - | $ | - | |||||||
| OPERATING EXPENSES | |||||||||||||||
| Administration expenses (including noncash compensation expense of | 6,219,644 | 53,068,147 | 14,446,391 | 53,442,499 | |||||||||||
| Occupancy expenses - related party | 10,917 | 6,469 | 32,306 | 20,187 | |||||||||||
| Research and development | 169,660 | 54,097 | 249,822 | 170,199 | |||||||||||
| TOTAL OPERATING EXPENSES | 6,400,221 | 53,128,713 | 14,728,519 | 53,632,885 | |||||||||||
| LOSS FROM OPERATIONS | (6,400,221 | ) | (53,128,713 | ) | (14,728,519 | ) | (53,632,885 | ) | |||||||
| OTHER INCOME (EXPENSE) | |||||||||||||||
| Interest expense | (38,270 | ) | (104,042 | ) | (402,874 | ) | (309,215 | ) | |||||||
| Interest income | 13 | 1 | 69 | 2 | |||||||||||
| Derivative expense | - | (59,271 | ) | - | (95,012 | ) | |||||||||
| Change in fair value of derivative liabilities | (18,146 | ) | 47,119 | 49,876 | 113,487 | ||||||||||
| Change in fair value of warrant liability | 182,517 | - | 776,227 | - | |||||||||||
| Other expense | 43,000 | - | (11,000 | ) | - | ||||||||||
| Settlement expense | (90,000 | ) | - | (90,000 | ) | - | |||||||||
| Gain (loss) on extinguishment of debt, net | (74,235 | ) | (809,954 | ) | 135,943 | (840,032 | ) | ||||||||
| Foreign currency transaction gain (loss) | 35,006 | (12,486 | ) | (19,190 | ) | (88,184 | ) | ||||||||
| TOTAL OTHER INCOME (EXPENSE), NET | 39,885 | (938,633 | ) | 439,051 | (1,218,954 | ) | |||||||||
| LOSS BEFORE TAXES | (6,360,336 | ) | (54,067,346 | ) | (14,289,468 | ) | (54,851,839 | ) | |||||||
| Tax benefit | - | - | - | - | |||||||||||
| NET LOSS | $ | (6,360,336 | ) | $ | (54,067,346 | ) | $ | (14,289,468 | ) | $ | (54,851,839 | ) | |||
| Deemed Dividend | - | - | (932,246 | ) | - | ||||||||||
| NET LOSS AVAILABLE TO COMMON STOCKHOLDERS | $ | (6,360,336 | ) | $ | (54,067,346 | ) | $ | (15,221,714 | ) | $ | (54,851,839 | ) | |||
| BASIC AND DILUTED NET LOSS PER SHARE | $ | (0.28 | ) | $ | (12.50 | ) | $ | (0.95 | ) | $ | (38.62 | ) | |||
| BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING | 22,427,486 | 4,325,994 | 15,973,535 | 1,420,307 | |||||||||||
| NET LOSS | $ | (6,360,336 | ) | $ | (54,067,346 | ) | $ | (15,221,714 | ) | $ | (54,851,839 | ) | |||
| OTHER COMPREHENSIVE INCOME (LOSS) | |||||||||||||||
| Unrealized foreign currency translation gain (loss) | (93,349 | ) | (27,311 | ) | (84,151 | ) | 194,976 | ||||||||
| TOTAL OTHER COMPREHENSIVE INCOME (LOSS) | (93,349 | ) | (27,311 | ) | (84,151 | ) | 194,976 | ||||||||
| TOTAL COMPREHENSIVE LOSS | $ | (6,453,685 | ) | $ | (54,094,657 | ) | $ | (15,305,865 | ) | $ | (54,656,863 | ) | |||
